Immunology Institute, Mount Sinai Medical Center, 1425 Madison Avenue, New York, NY 10029, USA.
J Gastroenterol. 2010;45(1):9-16. doi: 10.1007/s00535-009-0138-3. Epub 2009 Dec 4.
The pathogenesis of all immune-mediated inflammatory diseases has been carefully studied over the past several decades, but it is only recently that we have come to appreciate common pathways and genes. This is especially true for the inflammatory bowel diseases (IBD) Crohn's disease and ulcerative colitis, where a keener appreciation of the contributions of genetics, environment, and immune response have been dissected. In fact, in many ways, IBD has become the model for studying such disorders. The complex nature of interactions is continuing to be defined, and novel therapies targeting defects in these interactions have been developed and are being tested in the clinic. The era of bench to bedside has finally matured, and cures for debilitating diseases are now in sight. This review describes our current state of knowledge of each component of IBD pathogenesis. What has evolved is a clearer picture and novel targets for therapy.
过去几十年来，人们对所有免疫介导的炎症性疾病的发病机制进行了仔细研究，但直到最近，我们才开始认识到共同的途径和基因。对于炎症性肠病 (IBD) 中的克罗恩病和溃疡性结肠炎尤其如此，人们对遗传学、环境和免疫反应的贡献有了更深入的了解。事实上，在许多方面，IBD 已成为研究此类疾病的模型。相互作用的复杂性质仍在不断定义中，针对这些相互作用缺陷的新型疗法已经开发出来并正在临床中进行测试。从基础研究到临床应用的时代终于成熟，治疗致残性疾病的方法已经初见端倪。本文综述了我们目前对 IBD 发病机制各个组成部分的认识。所取得的进展是对治疗的目标有了更清晰的认识。
